Nanotechnology joins Immunology!

Advancing Virus-Free CAR-T Manufacturing Through Nanotechnology

At GenCART, our research team is exploring a virus-free approach to CAR-T cell manufacturing that represents a new frontier in cell therapy innovation.

Traditional CAR-T production methods rely on retroviral or lentiviral gene transfer, which, while effective, carry the inherent risk of insertional mutagenesis—a process where viral integration into the genome can unintentionally disrupt essential cellular genes, potentially affecting long-term safety.

To overcome these limitations, GenCART is working on a state-of-the-art nanotechnology-based gene delivery platform that enables precise, efficient, and stable modification of T cells without the use of viral vectors. This next-generation system employs synthetic nanoparticles engineered to deliver genetic material directly into the target cells, preserving cellular integrity while ensuring accurate expression of the therapeutic CAR construct.

By eliminating the need for viral vectors, GenCART’s virus-free nanotechnology platform aims to:

• Enhance patient safety by avoiding risks associated with insertional mutagenesis
• Simplify and accelerate manufacturing, enabling broader and more decentralized clinical application
• Reduce production costs, making CAR-T therapies more accessible to patients worldwide

This research embodies GenCART’s mission to redefine the future of cellular immunotherapy—safer, faster, and more accessible for every patient in need.